NPT
NVO

Nixon Peabody Trust’s Novo Nordisk NVO Stock Holding History

Nixon Peabody Trust’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,874
Closed -$247K – 157
2024
Q4 		$247K Buy
2,874
+800
+39% +$86.5K 0.02% 135
2024
Q3 		$247K Buy
+2,074
New +$277K 0.02% 126

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Nixon Peabody Trust's NVO Position: Q1 2025 in Review

Nixon Peabody Trust sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 2,874 shares — an estimated $247K sold.

Nixon Peabody Trust first reported a position in NVO in Q3 2024 and held it in 2 quarters. The position peaked at $247K in Q4 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Nixon Peabody Trust reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Nixon Peabody Trust sold 2,874 Novo Nordisk shares in Q1 2025, an estimated $247K.
  • Nixon Peabody Trust first reported a position in Novo Nordisk in Q3 2024 and held it in 2 quarters.
  • Nixon Peabody Trust's Novo Nordisk position peaked at $247K in Q4 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Nixon Peabody Trust's 13F filing for Q1 2025, filed 10 Apr 2025.